Altimmune to Present Promising Results of Pemvidutide at NASH-TAG Conference
Altimmune, a clinical-stage biopharmaceutical company, is set to present the results of its novel investigational drug, pemvidutide, at the upcoming NASH-TAG Conference. The conference, taking place on January 4-6, 2024 in Park City, UT, will feature the findings of a 24-week multicenter, randomized, double-blind, placebo-controlled trial.
The trial evaluated the effectiveness of pemvidutide in reducing liver fat in subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (previously known as Non-Alcoholic Fatty Liver Disease). The results showed a correlation between the reduction in liver fat and improvements in non-invasive markers of inflammation and fibrosis. This promising data will be presented in an abstract titled “Pemvidutide-Induced Liver Fat Reduction in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease Correlates with Improvements in Non-Invasive Markers of Inflammation and Fibrosis: Results of a 24-week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial” on Saturday, January 6, 2024.
Altimmune is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Its lead product candidate, pemvidutide, is a GLP-1glucagon dual receptor agonist being developed for the treatment of obesity and MASH (formerly known as NASH). The company is also developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B.
Altimmune’s strategic initiatives, including the development of pemvidutide and HepTcell™, have the potential to drive significant growth and value for the company. With its focus on treating obesity and liver diseases, two prevalent and growing health concerns, Altimmune is well-positioned as a key player in the biopharmaceutical industry.
Altimmune’s presentation at the NASH-TAG Conference highlights the company’s commitment to developing innovative treatments for obesity and liver diseases.
